• New LOI would allow the company to join development of a wide range of hemp-based medicinal products
• Neutra would also gain access to a cultivation license and a research license to examine the role of cannabinoids as antioxidants and neuro-protectants
• CBD sales in the U.S. expected to exceed $20 billion by 2024; hemp-based CBD product sales reached $390 in 2018 and are expected to more than triple over the next couple of years

Early-stage research and development company Neutra Corp. (OTC: NTRR) executed a Letter of Intent (LOI) that could lead to the joint development of a vast selection of additional hemp-based medicinal products on the booming CBD market, according to a company press release (http://ibn.fm/20ek4).

Neutra intends to conclude an agreement with Orgaceutical Co, based in Harrisburg, PA. If executed as planned, the agreement would provide Neutra with access to Orgaceutical’s formal research findings into the potential benefits of cannabinoids as antioxidants and neuro-protectants. Neutra, who is expanding into hemp cultivation and purified hemp extract products, would also gain a license for hemp cultivation issued by the Commonwealth of Pennsylvania’s Department of Agriculture as Orgaceutical Co is based in that state. The company would obtain rights to a federally registered hemp trademark as well.

According to Neutra CEO Sydney Jim, this agreement would help Neutra secure a solid position for research and development of new applications for hem-based CBD medicinal products. “With the cultivation license, we’ll have a constant and consistent supply of quality hemp under a vertically integrated cultivation model. With the research license, we’ll be free to explore new uses for hemp and products derived from it. Finally, with the trademark, we’ll have a federally protected brand name to pair with our existing VIVIS product line,” Jim said in a news release.

Neutra has been developing third-party certified hemp-derived CBD health and nutritional product lines for consumers for quite some time. The company recently acquired VIVIS, an emerging retail brand of hemp-based health and nutritional products. VIVIS has launched a soft gel CBD supplement, which was a crucial step in both its own and Neutra’s development as soft gel is the most efficient CBD ingestion method. This is because an entire dosage of CBD can be taken at once rather than spread out over time and lost to a great extent, as it would be when consumed in a beverage or a meal.

VIVIS’ hemp-derived CBD products are third-party certified as being of consistent quality and potency and free of contaminants. As global CBD markets become more strictly regulated, buyers are increasingly looking for certification when they buy these products. Neutra is expecting interest and demand for its expanding portfolio of branded products to increase with VIVIS as its new retail face.

Neutra recently signed a Letter of Intent to acquire J3 Holdings. This acquisition will include the latter’s land and warehouse as well as a license to cultivate hemp and refine it into usable forms. This approach will enable the company to grow its own hemp supply, giving it greater control over the selection of ingredients and allowing it to make sure they are of supreme quality.

The Orgaceutical LOI announcement came shortly after Neutra made the news earlier in October 2019 with its new CBD-based, menthol-infused sports cream, under the VIVIS brand (http://ibn.fm/Al8wk). With one in five Americans participating in a sport or exercising regularly, and a growing global sports nutrition market, the company expects considerable interest in its new product.

These recent developments give Neutra quite an advantage on the rapidly expanding CBD product market. BDS Analytics and Arcview Market Research project that the collective market for CBD sales in the U.S. will exceed $20 billion by 2024, with a 49 percent compound annual growth rate across all distribution channels (http://ibn.fm/yA3Kg). However, Neutra’s interests go above and beyond sales. “Most of our focus, obviously, is in our quality and potency of our products, because there is a vast difference between very cheap products and quality product,” Jim said in an exclusive interview with NetworkNewsWire. It takes a lot of time to extract CBD and make sure only the best quality is made available (http://ibn.fm/O97WF).

Neutra’s vastly expanding horizons include the commercialization of more innovative and effective products. The company is always looking for new opportunities to accelerate its mission to bring these products to a wider demographic. Neutra’s work reflects a strong commitment to supporting better health, environment, and quality of life for people around the world.

For more information, visit the company’s website at www.NeutraInc.com

NOTE TO INVESTORS: The latest news and updates relating to NTRR are available in the company’s newsroom at http://ibn.fm/NTRR

• HTC recently closed a bought deal private placement worth $10 million in funding
• Demand for hemp biomass continues to grow with the U.S. hemp-derived CBD market expected to reach $22 billion by 2022
• HTC’s proprietary biomass processing methodology maximizes extraction and purification of hemp biomass

After successfully raising $10 million in a private placement financing of 25 million units of the company, HTC Extraction Systems (TSX.V: HTC) is poised to expand its role in the cannabidiol (CBD) extraction market. HTC plans to use the funds for purchase of extraction, purification and refining equipment, and for general working capital purposes, the company stated in a news release (http://ibn.fm/kTlu9).

U.S. sales of hemp-based CBD products are expected to soar from 2018’s $591 million to $22 billion by 2022, growing at a CAGR of 147 percent, according to Brightfield Group (http://ibn.fm/Vk9wK). Brightfield also projects Canada’s cannabis industry will total $3.7 by the end of 2020, with derivatives such as CBD-infused edibles, vapes and topicals expected to generate $900 million next year (http://ibn.fm/4qXGf), largely due to new regulations allowing sales of the increasingly popular products.

With its proprietary hemp biomass extraction technology that reduces operating costs while delivering superior results, HTC Extraction Systems is uniquely positioned to take advantage of upcoming market opportunities such as derivative products (http://ibn.fm/YjP7P). CBD extracted from hemp biomass is infused in a wide array of derivative products such as oils, edibles, beverages, tinctures and topicals, which typically reap better margins and post higher price points.

HTC already has a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass, grown from five varieties of Health Canada-approved cultivars, from a hemp grower in Saskatchewan, Canada. HTC will process and extract CBD full spectrum oil (“FSO”) distillate from the hemp biomass and receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services (http://ibn.fm/o3G03).

Canada, which legalized limited forms of recreational cannabis for adult users in October 2018, marked the one-year anniversary on October 17, 2019, with regulations that allow sales of derivatives including edibles, vapes and topicals to consumers (http://ibn.fm/7IIWQ).

For more information, visit the company’s website at www.HTCExtraction.com

NOTE TO INVESTORS: The latest news and updates relating to HTC are available in the company’s newsroom at http://ibn.fm/HTC

• Predictive Oncology Inc. harnessing the power of artificial intelligence and its rich database of tumor data to help clinicians match cancer patients with most effective drug treatments
• Like Amazon’s customer dataset, POAI’s deep database of historical tumor information positions it for industry success
• Precision medicine is a data problem – demonstrates the huge value of data and those companies that generate it

When shopping on Amazon, it seems like the multinational technology company knows its customers intimately. Every product filtered into a search query response seems carefully curated to match each customer. This ability to leverage big data has pushed Amazon to the peak of success, and it now accounts for approximately 50 percent of all purchases made online (http://ibn.fm/0s6Qw).

Amazon’s success is a result of the company’s deep historical dataset of customer purchase profiles and its ability to leverage that with technologies such as AI. Across multiple industries from e-commerce, through finance to health care, there is now a recognition that data and the algorithms that help make sense of data are increasingly valuable and a key competitive differentiator.

From the health care field Predictive Oncology Inc. (NASDAQ: POAI) has been garnering industry attention as a hidden gem in the field of precision medicine for its innovative use of data and algorithms.

Precision Oncology is harnessing the power of artificial intelligence (think algorithms) to revolutionize treatment outcomes for cancer patients. What sets POAI apart from its competitors is the same factor that fueled Amazon’s rise: data. POAI (via its Helomics acquisition) has a huge proprietary database of tumor information, gathered from over 15+ years of clinical testing, which uniquely contains the drug responses of 150,000 individual patient tumors. Like Amazon’s database, which grows with each purchase, this unique tumor database grows daily as new tumors are tested.

While the use of data in cancer diagnostics is becoming more commonplace (think BRCA gene testing for breast cancer), for most patients the genomic data gathered from their tumor is not actionable, because researchers have a poor understanding of what mutations are important for choosing therapy. In the Amazon example, it would be like knowing people purchased dog food and cat litter but failing to predict they should buy cat food. POAI’s unique data on tumor drug response builds AI-driven predictive models that bring together the mutational and drug response profiles of the tumor to offer true actionable insights.

POAI is working with the pharmaceutical, diagnostic, and biotech industries to use its predictive models to both improve the development of new drugs (patients of tomorrow) as well as help clinicians individualize therapy (patients of today).

One disruptive aspect of POAI’s technology is that it helps the clinician to increase the chance of choosing more effective therapy, resulting in potential reduction of side-effects as well as cost savings. Traditionally oncologists prescribe what drugs they think have the best chance at beating a patient’s cancer, and the drug may or may not prove effective. Meanwhile, the patient’s undergoes chemotherapy with often debilitating side effects. If the drug proves to be a poor fit for the patient’s cancer, the chemotherapy experience will have been in vain, and the patient must continue acting as a guinea pig in experimenting with the next likely drug candidate. This is the standard cancer treatment of today. However, by utilizing POAI’s innovative tumor-profiling platform, which literally performs chemotherapy on the patient’s tumor outside the body to determine which drug is most effective, the patient can be spared many of the risks of being a “guinea-pig” as the oncologist attempts different drugs.

As Predictive leverages the data from its huge database of 150,000 of these “chemo outside the body” tests to build new predictive models, the ability to help the clinician choose the most effective drug for a patient cancer will improve. In addition, Predictive’s valuable predictive model will be a boon to the pharmaceutical industry in their race to develop new drugs to fight cancer.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• VPRB among key players anticipating United States Department of Agriculture (USDA) final draft rules on industrial hemp
• USDA’s Deputy Secretary Stephen Censky noted the regulations’ release to be expected within weeks, ahead of 2020 planting season
• Interim rules drafted include input from myriad voices; intend to relieve burden on producers, stakeholders

VPR Brands LP (OTCQB: VPRB), a multi-vertical tiered technology holding company in the cannabis space including vaping, joins other hemp industry players in their anticipation of the United States Department of Agriculture’s (USDA) release of an interim final rule for its Hemp Program. This announcement is timed in advance of the 2020 planting season and should guide producers with a framework for their activities (http://ibn.fm/fi3RB).

“We would expect to be issuing the interim final rule here within the next couple of weeks,” USDA deputy secretary Stephen Censky said in his testimony to the Senate Agricultural Committee. “We have been working in the interagency clearance process for over 90 days, working with some of our federal colleagues through the [White House Office of Management and Budget] process to get input there.” Censky noted that the committee is nearing the end of that process.

Censky referenced the work done by the USDA’s Agricultural Marketing Service (AMS) to prepare legislation for the upcoming growing session, much of which was influenced by key stakeholders. The committee sought to solicit stakeholder feedback through several avenues, including an open webinar listening session during March of 2019 where many voices were heard. The overall goal of the initiative, he noted, has been to eliminate conflict between producers and existing programs and to ensure that the “burden on producers and other stakeholders is minimized.”

Areas to be covered by the regulations include land use, certification, product testing and disposal of hemp containing excess THC (http://ibn.fm/tQ14Z). Censky said, “Many voices were represented during this listening session, and the insights offered during this and other stakeholder input were used by AMS to draft an interim rule.”

For hemp industry players like VPRB, this near-term release of an interim final rule on federal hemp regulations offers relief. A Hemp Program release prior to the 2020 planting season would provide direction to industry producers who seek a solid framework to guide their future activities.

Prior to 2018, industrial hemp production was prohibited because cannabis itself was a Schedule 1 controlled substance. While passage of the 2018 Farm Bill legalized the cultivation of industrial hemp, regulation is still catching up with the industry’s growth. For hemp industry stakeholders like VPRB that seek to execute strong strategy based on a solid foundation of growing practices, these regulations offer desired guidance.

VPR Brands employs a growth strategy centered on high-performance, high-quality products that build exponential brand equity, awareness and loyalty.

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at http://ibn.fm/VPRB

• ORHub Inc. is a health care intelligence company which develops data analytics software solutions to bring lean process improvement to the business of surgery
• ORHub developed Surgical Spotlight®, a program that is used to gather the real-time data from the operating room to provide comprehensive and intuitive dashboards used by physicians and administrators to help reduce costs and improve efficiency
• An interview done recently with Dr. Kevin Kaplan recaps the benefits of ORHub’s Surgical Spotlight®, and how he successfully applied the tool to his practice

ORHub Inc. (OTC: ORHB) is a health care intelligence company that is involved in the business of surgery. ORHub Inc. is a SaaS-based health care data analytics company. The company aims to help operating rooms in hospitals to function at their best by providing analytical tools such as the cloud-based Surgical Spotlight. ORHub is also a Microsoft Silver partner leveraging the Azure cloud for services to make the data more easily and readily available to clients.

A recent interview done with Dr. Kevin Kaplan, MD, regarding his use of Surgical Spotlight® that ORHub developed (http://ibn.fm/tfH4X). Kaplan, the head team doctor of the Jacksonville Jaguars, is interested in improving the efficiency and costs associated with surgeries being performed on a daily basis in a high-volume practice at Baptist Medical Center. He is a top orthopedic surgeon always looking to improve the OR efficiency while improving his care for patients.

Surgical Spotlight® uses a set of curated key performance indicators (KPIs), and dynamic dashboards that clients can use to quickly view and evaluate what is happening in the OR. The performance indices include metrics such as cadence, on-time starts, volume, cancellations, schedule accuracy, block and staff utilization, and cost per case. These are all critical measures to evaluate where opportunities for celebration or improvement in any surgical business, leading to behavior change and team collaboration.

Kaplan in the interview specifically highlights the value of the cost per case metric in his practice, and how this performance indicator has helped him evaluate his cost is for each procedure. He also discusses how challenging it is to know what factors are contributing to the high cost and inefficiency within an operating room and during a particular surgical case without regular information. Today, the very high cost of medicine and medical care is a cause for concern since this directly impacts patient care and knowing how to cut costs and make the best and most efficient use of medical resources is a big benefit for medical centers.

Kevin Kaplan discusses how Surgical Spotlight® helps to bridge the gap between the businesspeople and the surgeons in a busy medical practice, by providing data that physicians can view in real time. In Kaplan’s experience, Physicians often do not know very much about the business side of medicine since this is not an area they are trained in. The data gathered in Surgical Spotlight® shows surgeons what is happening before and during cases and also between cases in the OR.

In addition, information from the program provides insight into how money is being spent – which means that the doctors are able to evaluate material usage to determine if there are ways to save costs, which benefits all parties including the hospital and patients. In fact, Kaplan explained how the use of Surgical Spotlight® has already led to cost-saving measures for such operations as ACL reconstructions and rotator cuff surgeries, which he routinely performs as an orthopedic surgeon.

Surgical Spotlight® also provides a series of automated reports; such as a weekly facility report, quarterly executive update, monthly service line scorecard in addition to the daily surgical receipt. The daily receipt gives information on the data captured each day. A block utilization report can also be generated by the program. This means that the software can help surgeons with high utilization illustrate their need for increased block time or if another operating room should be opened.

ORHub has also ensured that Surgical Spotlight® can be quickly implemented within about one month. The software used is not limited to operating rooms or single procedural types, and can also be used in cath labs, for instance. Surgical Spotlight® does not need to be integrated with any EHR (http://ibn.fm/Nwsp9). This means that there are no compatibility issues with respect to any EHRs being used in the medical center. ORHub uses a pay-per-use pricing program which proves to be advantageous for their clients.

For more information, visit the company’s website at www.ORHub.com

NOTE TO INVESTORS: The latest news and updates relating to ORHB are available in the company’s newsroom at  http://ibn.fm/ORHUB

• CloudCommerce’s business intelligence solution, SWARM, incorporates micro-targeting tools
• The exclusive solution is backed by CloudCommerce subsidiaries’ expertise and technologies
• The business intelligence market is forecast to reach $34.3 billion by 2022

Micro-targeting is now available to brand distributers and other marketers, thanks to organizations such as CloudCommerce Inc. (OTCQB: CLWD). The company, a provider of audience-driven business-intelligence and marketing solutions, has developed a menu of tools that utilizes consumer data and demographics to create audience subsets or segments. This information allows businesses to deliver fine-tuned marketing communications that are not only more effective because they are free of irrelevant messaging, but they also cost less.

Micro-targeting is only one instrument in the CloudCommerce tool kit. The company has developed SWARM, a comprehensive audience-intelligence solution that helps businesses identify who to talk to, what to say to them, and how to motivate them to take meaningful action.

Micro-targeting is a big deal, an integral part of the social-media advertising market, which in 2017 was worth $43.78 billion (http://ibn.fm/O57N7). Long the Holy Grail of marketers, social-media advertising has become finely tuned, spurred by the spread of digital technologies, which generate a wealth of consumer data. Algorithms track and capture consumer online behavior, analyzing everything from browsing habits to social media posts and purchases.

This information is then mapped to demographic, geographic and psychographic attributes, and the resulting universe of data is dissected to discern patterns, which has been shown to predict interests, opinions and buying behavior. As a result, marketers can deliver targeted messages recipients want to hear, ones that likely will be of value to them. No more intrusive advertising and hard-sell tactics. Micro-targeting delivers welcome advertising that informs, educates and entertains.

CloudCommerce’s flagship solution, SWARM, utilizes a wide range of methodologies to discover, develop and create custom audiences for any business activity (http://ibn.fm/hmxjU). These techniques are drawn from diverse disciplines including advanced data science, behavioral science, artificial intelligence, and marketing research. Using SWARM, marketers can examine consumer motivations and the factors that trigger consumers’ decisions to buy. Promoters then have the opportunity to communicate more effectively with their prospects, leading to greater brand acceptance and increased revenues. SWARM is backed by a range of complimentary services offered by subsidiaries.

CloudCommerce is targeting SWARM at the fast-growing business-intelligence market. According to Market Research Future, this market is expected to grow at a compound annual growth rate (CAGR) of 11.03 percent, reaching $34.3 billion by 2022 (http://ibn.fm/MN7Ee).

DataPROPIA provides a data-analytic service that collects, aggregates, and analyzes data from a wide variety of sources. The data is then analyzed to generate input for targeted marketing campaigns. DataPROPIA has data-analytics expertise in retail, wholesale, distribution, logistics, manufacturing, and several other industries.

Parscale Digital focuses on digital marketing. The subsidiary has a history of developing marketing plans for clients that execute powerful call-to-action digital campaigns that boost exposure and widen national reach. Giles Design Bureau is the group’s branding specialist subsidiary, while WebTEGRITY focuses on web design by developing commerce-focused, user-friendly digital websites and apps for online marketers.

For more information, visit the company’s website at www.CloudCommerce.com

NOTE TO INVESTORS: The latest news and updates relating to CLWD are available in the company’s newsroom at http://ibn.fm/CLWD

• CBD is a key piece of VPR Brands’ product development and marketing, with its GOLDLINE CBD products serving as a significant new entrant into the space
• The company recently exhibited its new GOLDLINE product offerings, including CBD oil, CBD-oil cartridges, gummies and CBD-oil tinctures, at NACS Expo
• VPRB grew sales to $1.58 million in Q2 2019, marking a 31 percent jump from the comparable period of the prior year

VPR Brands LP (OTCQB: VPRB), a multi-vertical tiered technology holding company in the cannabis space, is expanding and focusing on CBD products as the term ‘CBD’ is itself becoming more significant in social media. In a Google Trends study (http://ibn.fm/GNXmR) of keyword trend usage, CBD was found to be far more popular as a keyword trend than icons such as Kim Kardashian or the trending ‘veganism’ term (http://ibn.fm/XQW6t). The public is curious about CBD, which positions companies like VPR Brands for enhanced market penetration.

The Google Trends findings on keyword usage saw a rise in the term CBD far outpacing popular social-media personalities or food trends. An October 23 analysis (http://ibn.fm/52bTJ) shows that CBD recorded a keyword value of 55 compared to only 30 for Kim Kardashian, 23 for Taylor Swift, and less than one for veganism.

That social-media interest doesn’t simply exist in cyberspace. Real-life behavior reflects a growing acceptance and use of marijuana and its multifaceted components. A GOLDLINE CBD blog concludes that “about 52 percent of Americans either smoke pot or have tried smoking pot. That’s a huge portion of the American population to add to the level of popularity that CBD has.”

VPRB is recognizing this growing interest and is focusing on CBD products. The company recently exhibited its new GOLDLINE CBD hemp-derived, multiproduct line at the National Association of Convenience Stores (NACS) Expo in Atlanta (http://ibn.fm/6rzsi). GOLDEN CBD includes CBD oil, CBD-oil cartridges, gummies, and CBD-oil tinctures.

“The ‘Green Rush’ has a long future ahead of it, and CBD is one of the biggest subcategories within the cannabis business,” the blog observed. “With that being said, CBD GOLDLINE is proud to stay ahead of the curve when it comes to cutting-edge products and CBD-derived products that are safe and all-natural.”

VPRB is ideally positioned at the intersection of two industries trending toward smokeless products: nicotine and cannabis. According to Grand View Research Inc., the company reports that cannabis is projected to be a $146.4 billion global market by 2021 and the nicotine market will reach $47.11 billion globally by 2025 (http://ibn.fm/bQJtN).

VPR Brands is committed to being a part of that burgeoning market, and the company’s recent financial report is a testament to its ability to accomplish that goal. VPRB reported a significant increase in sales for Q2 2019 for the three months ended June 30 to $1.58 million, a 31 percent jump from the comparable period the prior year (http://ibn.fm/7puL1).

For more information, visit the company’s website at www.VPRBrands.com

NOTE TO INVESTORS: The latest news and updates relating to VPRB are available in the company’s newsroom at  http://ibn.fm/VPRB

• The success of the pilot project opens up exciting possibilities for OriginClear in animal-wastewater treatment space
• OriginClear has partners in Europe’s top two hog-production markets
• The need for on-premises water treatment is growing as central facilities fail and treatment costs rise

OriginClear Inc. (OTC: OCLND) CEO Riggs Eckelberry and President Bill Charneski provided an impressive update during a recent CEO briefing, discussing the success of a pilot project the company is spearheading in Spain (http://ibn.fm/2ipzM). The project combines OriginClear’s proprietary Electro Water Separation™ technology with its exclusive Advanced Oxidation process (AOx) that recycles manure water into clean, usable water (http://ibn.fm/ffjKK).

The pilot project, which has been ongoing since 2017, involves OCLN scientists and researchers at the company’s Spanish licensee, Depuporc, running raw manure through OriginClear’s own EWS and AOx™ process. Clear water emerges, reported Charneski, water that is free of organics, phosphorus, nitrates, and ammonia. Charneski and Eckelberry also noted that the term “pilot” system doesn’t indicate a small endeavor; the system in Spain is capable of processing up to 30 metric tons a day.

This exciting news may open up the animal effluent segment to OriginClear. As the world’s third-largest pork exporter, Spain is home to more than 28 million animals and presents an ideal potential market, as do the top-two exporters: China and the United States. OriginClear is also working with a partner in Romania, the second-largest producer of pork in Europe, which means the company has licensees in the top two hog-production markets in Europe.

Charneski is heading to Spain for a full-documentation, onsite visit, and the two company officials noted that a formal announcement with complete details and testimonials will be provided after his return.

The report on the Spanish pilot project came as Eckelberry expounded on the mounting need for on-premises water treatment. An advanced player in the decentralized water revolution, OriginClear is playing a key role in meeting the need through its Instant-Infrastructure Modular Water Systems™ products (http://ibn.fm/8XK6L).

As central water-treatment facilities around the country fail and the cost of water treatment only goes up, businesses are seeking other options. OriginClear’s prefabricated, drop-in-place systems offer lower water costs through water reuse, higher water quality, and higher Environmental, Social and Governance (ESG) ratings through better water management—an accreditation that top companies are striving to achieve. Eckelberry noted that the company continues to bid on and close a growing number of jobs.

OriginClear leads the self-reliant water revolution, deploying advanced technologies at the point of use, with modular, prefabricated systems that create durable assets and water independence for industry, commerce and agriculture. OriginClear’s on-premise systems enable very high purification and recycling levels that centralized systems cannot achieve. Systems installed at the point of use become productive assets that increase business and property values.

For more information, visit the company’s website at www.OriginClear.com

NOTE TO INVESTORS: The latest news and updates relating to OCLN are available in the company’s newsroom at http://ibn.fm/OCLN

• B2Digital Inc. has organized a premier development league for mixed martial arts competitors that includes a 10-event fall season currently under way across 10 states, with an extended reach via social media and online video
• Over the past decade, mixed martial arts has seen remarkable growth in worldwide popularity that has positioned it as the third most popular sport behind soccer and basketball
• B2Digital recently filed with the U.S. Securities and Exchange Commission establishing itself as a fully reporting company intent on showing its ability to attract a higher level of shareholder interest

The growth in popularity of mixed martial arts (MMA) during the past decade to a lofty position where it ranks just behind soccer and basketball as the world’s third most popular sport has opened a potential bonanza for the people who can properly organize and promote a good fight.

MMA athletes combine boxing, judo, karate, wrestling and other disciplines in cage matches that have drawn nearly a half billion fans, according to Nielsen Sports DNA, the vast majority of them from outside the United States (http://ibn.fm/eP1JL).

Sports entertainment company B2Digital Inc. (OTC: BTDG) has steadily shown its backbone for battle since it restructured two years ago with the launch of its own premier MMA development league as well as two training facilities for fighters and a social media network that keeps fans connected as the action unfolds.

B2Digital aims to build its B2 Fighting Series champions to the point that their fighters can move on to the MMA major leagues, providing audiences in Indiana, Iowa, Ohio, Michigan, Illinois, Kentucky, Tennessee, West Virginia, Alabama and Mississippi a rousing season of live competitive events with video viewer access in the process (http://ibn.fm/ZEBH6). The geographical focus will remain on states in the Midwest, South and Central regions where viewership is the highest.

The company is now in line to uplist on the OTC Exchange after becoming a fully reporting business with the U.S. Securities and Exchange Commission (SEC) this month, filing a Form 8-A Registration Statement that will open the way for increased investment potential exposure.

“We believe that becoming a fully-reporting company subject to the reporting requirements of the SEC shows our commitment to providing current public information to not only our deserving and valued shareholders but to the public, in general,” Chairman and CEO Greg P. Bell stated in a news release (http://ibn.fm/XE7v6). “Being a fully reporting company with the SEC should also help contribute to increased liquidity for our current and future shareholders and will enhance management’s accountability.”

B2Digital acquired HRMMA and Colosseum Combat in 2017 and United Combat League, Pinnacle combat and Strike Hard Productions in 2019 and maintains the acquisition of existing and operating MMA fight groups as a key part of its strategy. The company also continues to build its social network, which passed 3.9 million connections to consumers during the second quarter, and is developing ways to monetize the B2SN audience (http://ibn.fm/tKKP2).

The viewership amounted to 4,902 hours of B2Digital video, both live and on-demand, which was an increase of 45 percent. While 95 percent of the B2SN audience is in the United States, the network reached 24 other countries, including nearly all of the Americas and Asia.

For more information, visit the company’s website at www.B2DigitalOTC.com

NOTE TO INVESTORS: The latest news and updates relating to BTDG are available in the company’s newsroom at http://ibn.fm/BTDG

• PLUS recently appointed a respected researcher, Dr. Ari Mackler, as its chief scientific officer to oversee the company’s research and education efforts
• The company’s CEO believes that Mackler will play an invaluable role in PLUS’ forward operations, positioning it among industry thought leaders
• The new CSO joins a proven team of professionals, including former CPG executives, chefs, chemists and food-manufacturing experts

Plus Products Inc. (CSE: PLUS) (OTCQX: PLPRF), a leading cannabis-branded product company with the two best-selling cannabis products in California, is committed to careful, deliberate product research, formulation and delivery. As part of the company’s strategic plan to strengthen its reputable brand, PLUS has named its first-ever chief scientific officer, Dr. Ari Mackler (http://ibn.fm/qWiaJ).

With 20 years of medical affairs, communications, and research experience in pharmaceutical, healthcare, and consumer goods industries, Mackler brings with him an impressive list of accomplishments and valuable professional experience.

“I have been intrigued by cannabis for years and saw a huge opportunity to apply my scientific and consumer products background for PLUS to help validate and articulate how their products may help people live better lives,” Mackler, who most recently was vice president of clinical development for the Wonderful Company, stated in a news release. “I also believe scientifically based education is vital to the future of the industry, and PLUS has focused their business processes in a way that ensures science is at the center of their product development DNA.”

Adding Mackler to the PLUS team represents the company’s deep commitment to intentional product development and offerings. “Dr. Mackler has a long history of helping consumer product companies share a clear and scientifically backed narrative around product benefits,” PLUS co-founder and CEO Jake Heimark stated in a news release. “Cannabis is a performance category, and the most successful brands will be those that understand and are able to clearly communicate why their products work. There are few researchers of Dr. Mackler’s caliber in the cannabis industry today, and we believe he will play an invaluable role not only for PLUS but as a thought leader within the industry.”

At the Wonderful Company, Mackler oversaw company health and wellness initiatives and was integrally involved in efforts to help the business become a global branded-products leader. He has also held positions with the multinational pharmaceutical company Merck & Co, the Almond Board of California, the International Tree Nut Council, the Nutritional Research & Education Foundation, and Stem Cell Resource.

At PLUS, Mackler will focus on establishing research relationships and clinical trials with academic institutions and private partners. These partnerships will be aimed at growing and strengthening consumer understanding of cannabis and its benefits. Mackler joins Plus Products’ outstanding product team of professionals, which includes Michelin-star sous chefs, chemists, and food-manufacturing experts.

Plus Product’s purposeful approach to product development and its expert team have already established a successful track record. The company currently boasts two of the top-selling cannabis products in California: Restore – Indica Blackberry Lemon Gummies (20 pack) and Sour Watermelon Gummies (20 pack).

PLUS cannabis-infused edibles are available in more than 360 licensed retailers across the state of California, and the company recently launched its products in Nevada, one of the nation’s most promising cannabis markets. In addition, PLUS unveiled a line of 100 percent hemp-CBD-infused gummies, available on its website.

For more information, visit the company’s website at www.PlusProducts.com

NOTE TO INVESTORS: The latest news and updates relating to PLPRF are available in the company’s newsroom at http://ibn.fm/PLPRF